tyrosine kinase inhibitor

News

Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC

02/15/2021

Journal of Clinical Pathways

News

TKI Discontinuation Associated With Improved PROs in CML

12/03/2020

Journal of Clinical Pathways

Research in Review

Second TKI Discontinuation Attempt Safe in Patients With CML

07/27/2017

JCP Editors

Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...

...

07/27/2017

Journal of Clinical Pathways

From the Field

Mock Clinical Pathways: A Method for Exploring the Oncology Clinical Pathway Development Process

05/06/2016

Bing-E Xu , PhD;

Bruce A. Feinberg , DO;

Monica Lingam , MS;

Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...

...

05/06/2016

Journal of Clinical Pathways